skip to main content

Valproate pregnancy prevention — GPhC CRA MCQ

Instant feedback + full explanation. One question, done properly.

HardCNS TherapeuticsValproate pregnancy preventionGPhC CRA

A 20-year-old woman presents a repeat prescription for sodium valproate modified-release tablets. The pharmacy record shows no recent documentation of a pregnancy prevention programme discussion. What is the most appropriate action?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Check pregnancy prevention programme requirements before supply and contact the prescriber if needed

Valproate is highly teratogenic and is subject to strict pregnancy prevention programme requirements in patients who can become pregnant. A pharmacist should not abruptly stop an established antiseizure medicine, as this may cause harm. The appropriate action is to check the required documentation and liaise with the prescriber where it is absent or unclear. Folic acid does not remove the teratogenic risk.

Reference: MHRA Drug Safety Update; BNF